补体因子H与心血管疾病的研究进展

朱成振; 张醒; 郭皓

doi:10.12259/j.issn.2095-610X.S20210828

补体因子H与心血管疾病的研究进展

doi: 10.12259/j.issn.2095-610X.S20210828

昆明医科大学第一附属医院心内科，云南昆明　650032

基金项目: 国家自然科学基金资助项目（81660078）；云南省医学学科带头人培养计划基金资助项目（D-2017015）；云南省科技厅-昆明医科大学应用基础研究联合专项面上基金资助项目[2019FE001（-215）]；高层次科技人才及创新团队选拔专项-中青年学术和技术带头人后备人才基金资助项目（202005AC160053）；云南省心脑血管疾病临床医学中心建设基金资助项目（ZX2019-03-01）

详细信息

作者简介:
朱成振（1987～），男，江苏徐州人，在读硕士研究生，主要从事高血压和心脏康复基础与临床研究工作

通讯作者:
郭皓，E-mail：guohaodoc@163.com

中图分类号: R541.3
计量
- 文章访问数: 3319
- HTML全文浏览量: 3074
- PDF下载量: 56
- 被引次数: 0
出版历程
- 收稿日期: 2021-03-28
- 网络出版日期: 2021-08-04
- 刊出日期: 2021-08-04

Advances on Complement Factor H and Cardiovascular Disease

Dept. of Cardiology，The 1st Affiliated Hospital of Kunming Medical University， Kunming Yunnan 650032，China

摘要

摘要: 心血管疾病严重威胁人类健康，具有高发病率、高致死率和高致残率的特点。近年来研究发现，补体因子H（complement factor H，CFH）是补体系统和炎症反应中非常重要的负性调节因子。CFH的减少或缺如可使补体旁路途径持续激活及介导的炎症反应增强，导致血管内皮细胞和心肌细胞等损伤。CFH在心血管疾病的发病中扮演着重要的角色并参与了其病理生理学机制。现系统综述CFH在心血管疾病发病中的作用及机制。
- 补体系统 /
- 补体因子H /
- 心血管疾病
Abstract: Cardiovascular diseases is a serious threat to human health, which is characterized by high morbidity, high lethality and disability. In recent years, studies have found that complement factor H （CFH） is a very important negative regulator in the complement system and inflammatory response. The decrease or absence of CFH can continuously activate the complement alternative pathway and enhance the mediated inflammatory response, leading to damage of endothelial cells and cardiomyocytes. CFH plays an important role in the pathogenesis of cardiovascular disease and is involved in the pathophysiology mechanism. This article reviewed the role and mechanism of CFH in the pathogenesis of cardiovascular disease.
- Complement system /
- Complement factor H /
- Cardiovascular diseases

HTML全文

参考文献(34)

[1]	Friese M A,Hellwage J,Jokiranta T S,et al. Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA)[J]. Clin Exp Immunol,2000,121(2):406-415. doi: 10.1046/j.1365-2249.2000.01285.x
[2]	Jokiranta T S,Hellwage J,Koistinen V,et al. Each of the three binding sites on complement factor H interacts with a distinct site on C3b[J]. J Biol Chem,2000,275(36):27657-27662. doi: 10.1074/jbc.M002903200
[3]	Friese M A,Hellwage J,Jokiranta T S,et al. FHL-1/reconectin and factor H:two human complement regulators which are encoded by the same gene are differently expressed and regulated[J]. Mol Immunol,1999,36(13-14):809-818. doi: 10.1016/S0161-5890(99)00101-7
[4]	Rodriguez de Cordoba S,Esparza-Gordillo J,Goicoechea de Jorge E,et al. The human complement factor H:functional roles,genetic variations and disease associations[J]. Mol Immunol,2004,41(4):355-367. doi: 10.1016/j.molimm.2004.02.005
[5]	李建国,肖慧捷,杨霁云. 补体H因子研究进展[J]. 国外医学(儿科学分册),2005,32(3):143-146.
[6]	Cserhalmi M, Papp A, Brandus B, et al. Regulation of regulators: Role of the complement factor H-related proteins[J]. Semin Immunol, 2019, 45: 101341.
[7]	De Córdoba S R,De Jorge E G. Translational mini‐review series on complement factor H:genetics and disease associations of human complement factor H[J]. Clinical & Experimental Immunology,2008,151(1):1-13.
[8]	Parente R,Clark S J,Inforzato A,et al. Complement factor H in host defense and immune evasion[J]. Cell Mol Life Sci,2017,74(9):1605-1624. doi: 10.1007/s00018-016-2418-4
[9]	Laine M,Jarva H,Seitsonen S,et al. Y402H polymorphism of complement factor H affects binding affinity to creactive protein[J]. The Journal of Immunology,2007,178(6):3831-3836. doi: 10.4049/jimmunol.178.6.3831
[10]	Clark S J,Bishop P N. Role of factor H and related proteins in regulating complement activation in the macula,and relevance to age-related macular degeneration[J]. Journal of Clinical Medicine,2015,4(1):18-31.
[11]	Goodship T H,Cook H T,Fakhouri F,et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy:Conclusions from a “Kidney disease:Improving global outcomes”(KDIGO) controversies conference[J]. Kidney International,2017,91(3):539-551. doi: 10.1016/j.kint.2016.10.005
[12]	Montaniel K R,Harrison D G. Is hypertension a bone marrow disease?[J]. Circulation,2016,134(18):1369-1372. doi: 10.1161/CIRCULATIONAHA.116.024520
[13]	Ruan C C,Gao P J. Role of complement-related inflammation and vascular dysfunction in hypertension[J]. Hypertension,2019,73(5):965-971. doi: 10.1161/HYPERTENSIONAHA.118.11210
[14]	Fritsche L G,Lauer N,Hartmann A,et al. An imbalance of human complement regulatory proteins CFHR1,CFHR3 and factor H influences risk for age-related macular degeneration (AMD)[J]. Human Molecular Genetics,2010,19(23):4694-4704. doi: 10.1093/hmg/ddq399
[15]	Engström G,Hedblad B,Berglund G,et al. Plasma levels of complement C3 is associated with development of hypertension:A longitudinal cohort study[J]. Journal of Human Hypertension,2007,21(4):276-282. doi: 10.1038/sj.jhh.1002129
[16]	Chen L,Fukuda N,Matsumoto T,et al. Role of complement 3 in the pathogenesis of hypertension[J]. Hypertens Res,2020,43(4):255-262. doi: 10.1038/s41440-019-0371-y
[17]	Chen L,Fukuda N,Otsuki T,et al. Increased complement 3 with suppression of miR-145 Induces the synthetic phenotype in vascular smooth muscle cells from spontaneously hypertensive rats[J]. J Am Heart Assoc,2019,8(10):e012327.
[18]	Zhang C,Li Y,Wang C,et al. Complement 5a receptor mediates angiotensin II–Induced cardiac inflammation and remodeling[J]. Arteriosclerosis,Thrombosis,and Vascular Biology,2014,34(6):1240-1248. doi: 10.1161/ATVBAHA.113.303120
[19]	GAN W,WU J,LU L,et al. Associations of CFH polymorphisms and CFHR1-CFHR3 deletion with blood pressure and hypertension in Chinese population[J]. PloS One,2012,7(7):e42010. doi: 10.1371/journal.pone.0042010
[20]	Wong T Y,Tikellis G,Sun C,et al. Age-related macular degeneration and risk of coronary heart disease:The atherosclerosis risk in communities study[J]. Ophthalmology,2007,114(1):86-91. doi: 10.1016/j.ophtha.2006.06.039
[21]	Hageman G S,Anderson D H,Johnson L V,et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration[J]. Proceedings of the National Academy of Sciences,2005,102(20):7227-7232.
[22]	Klein R,Knudtson M D,Klein B E,et al. Inflammation,complement factor h,and age-related macular degeneration:the Multi-ethnic Study of Atherosclerosis[J]. Ophthalmology,2008,115(10):1742-1749. doi: 10.1016/j.ophtha.2008.03.021
[23]	Giannakis E,Male D,Ormsby R,et al. Multiple ligand binding sites on domain seven of human complement factor H[J]. Int. Immunopharmacol,2001,1(3):433-443. doi: 10.1016/S1567-5769(00)00040-0
[24]	Pai J K,Manson J E,Rexrode K M,et al. Complement factor H (Y402H) polymorphism and risk of coronary heart disease in US men and women[J]. European Heart Journal,2007,28(11):1297-1303. doi: 10.1093/eurheartj/ehm090
[25]	孙彩琴,陈忠,马根山,等. 早发冠心病患者血浆补体因子H浓度检测及其临床意义[J]. 实用临床医药杂志,2008,12(1):88-89. doi: 10.3969/j.issn.1672-2353.2008.01.024
[26]	钱琦,陈忠,马根山,等. 血浆补体因子H、超敏C反应蛋白和胰岛素抵抗与冠心病的关系[J]. 江苏医药,2009,35(4):382-384.
[27]	Nicaud V,Francomme C,Ruidavets J-B,et al. Lack of association between complement factor H polymorphisms and coronary artery disease or myocardial infarction[J]. Journal of Molecular Medicine,2007,85(7):771-775. doi: 10.1007/s00109-007-0185-2
[28]	孙彩琴,陈忠,马根山. 补体因子H基因^127T/C多态性与早发冠心病的相关性研究[J]. 交通医学,2008,22(6):606-608. doi: 10.3969/j.issn.1006-2440.2008.06.005
[29]	Yndestad A,Damas J K,Qie E,et al. Role of inflammation in the progression of heart failure[J]. Current Cardiology Reports,2007,9(3):236-241. doi: 10.1007/BF02938356
[30]	Suffritti C,Tobaldini E,Schiavon R,et al. Complement and contact system activation in acute congestive heart failure patients[J]. Clinical & Experimental Immunology,2017,190(2):251-257.
[31]	Shahini N,Michelsen A E,Nilsson P H,et al. The alternative complement pathway is dysregulated in patients with chronic heart failure[J]. Scientific Reports,2017,7(42532):2045-2322.
[32]	Hovland A,Jonasson L,Garred P,et al. The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis[J]. Atherosclerosis,2015,241(2):480-494. doi: 10.1016/j.atherosclerosis.2015.05.038
[33]	Ge X,Xu C,Liu Y,et al. Complement activation in the arteries of patients with severe atherosclerosis[J]. Int J Clin Exp Pathol,2018,11(1):1-9.
[34]	An G,Li B,Liu X,et al. Overexpression of complement component C5a accelerates the development of atherosclerosis in ApoE-knockout mice[J]. Oncotarget,2016,7(35):56060-56070. doi: 10.18632/oncotarget.11180

相关文章(20)

[1]	刘怡涵, 刘俊, 金永梅, 田波, 白劲松. HIV抗病毒治疗患者心血管疾病风险评估及危险因素分析, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20241022
[2]	张露, 李叶, 王晴晴, 李生浩. 肝硬化对心血管系统的影响及相关机制研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240601
[3]	陈珮琪, 杨宗璐, 赵玲, 杜士刚, 杨璐, 李诗雨, 戴雨如, 柯亭羽. 不同评估方法在T2DM 心血管病风险评估中的应用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220406
[4]	娄雪, 廖莉, 赵若彤, 王湘宇, 杨一帆, 刘爽, 徐健. 抗dsDNA抗体、补体C3及其他实验室指标对于诊断系统性红斑狼疮肾损伤的临床意义, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210214
[5]	颜玲玲, 钱志宏, 倪悦, 吴煌. 维生素D及钙补充影响POP人群心脑血管类疾病发生的临床调查, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211036
[6]	何建辉. 云南省某农村地区体重相关指数分布与心血管疾病的关系, 昆明医科大学学报.
[7]	李云萍. 情景模拟在心血管介入护理实践教学中的应用, 昆明医科大学学报.
[8]	曹丰. 云南省玉龙县纳西族心血管疾病危险因素聚集性的社会经济影响研究, 昆明医科大学学报.
[9]	杨眉舒. 昆明市高职业压力护士心血管疾病危险因素患病分析, 昆明医科大学学报.
[10]	马娟. 184例心血管疾病患者吸烟及戒烟现状调查分析, 昆明医科大学学报.
[11]	光雪峰. 心血管疾病诊疗进展, 昆明医科大学学报.
[12]	杨荆. 血透患者血尿酸水平80例临床分析, 昆明医科大学学报.
[13]	杨荆. 血透患者血尿酸水平80例临床分析, 昆明医科大学学报.
[14]	蔡瑛. 艾司洛尔对全麻拔管期心血管反应的临床观察, 昆明医科大学学报.
[15]	余梅. 心血管系统疾病患者牙龈出血诊疗分析, 昆明医科大学学报.
[16]	. 心血管外科进展, 昆明医科大学学报.
[17]	李俊. 维持性血液透析患者微炎症状态与心血管并发症相关性研究, 昆明医科大学学报.
[18]	张学玉. 昆明市官渡区心血管疾病患病与危险因素聚集性的关系调查分析, 昆明医科大学学报.
[19]	王慧明. 艾司洛尔预防气管插管心血管反应的临床观察, 昆明医科大学学报.
[20]	杨秋萍. 心血管危险因素聚集与心率变异性的关系研究, 昆明医科大学学报.